Examining the Circadian Timing Effects of the Hypotensive Response to Exercise
NCT07049783
Recruiting
The goal of this study is to learn how exercise timing affects blood pressure in adults with elevated or high blood pressure. Exercise can influence the body's natural 24-hour rhythms, including blood pressure patterns. A single exercise session can lower blood pressure for up to 24 hours, but it is not fully understood how the time-of-day for exercise affects this response. The main question this study aims to answer is: • When the same participant exercises at different times of day (morning,... Read More
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
08/12/2025
Locations: University of Delaware, Newark, Delaware
Conditions: Young Adults, Hypertension, Post-Exercise Hypotension, Circadian Rhythm
Register for Updates
Self-discontinuation of Urinary Catheters in a Rural Population
NCT07041151
Recruiting
The goal of this study is to understand patient satisfaction with two different ways of managing difficulty urinating after gynecologic surgery with a focus on those patients who receive care in a rural area. One common practice is to have an "office catheter removal." This means, if a patient has trouble urinating after surgery and goes home with a foley catheter, they usually have to come back to the clinic within 2-3 days to have the catheter removed and to do a test to see if they can urina... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire +1 locations
Conditions: Post-Operative Urinary Retention
Register for Updates
A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear
NCT07054606
Recruiting
Assess the impact of concomitant Miebo use while wearing contact lenses
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Site 101, San Diego, California +7 locations
Conditions: Dry Eye
Register for Updates
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
NCT07076407
Recruiting
X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
08/12/2025
Locations: California Neuroscience Research, Sherman Oaks, California +2 locations
Conditions: Major Depressive Disorder
Register for Updates
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
NCT06979596
Recruiting
Researchers want to learn if MK-5684 (the study medicine) can treat breast cancer, ovarian cancer, and endometrial cancer. MK-5684, the study medicine, is designed to treat cancer by blocking the body from making steroid hormones. Researchers will compare MK-5684 to the standard treatments for each cancer type in this study. The goal of this study is to learn if people who receive MK-5684 live longer without the cancer growing or spreading compared to people who receive a standard treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Mount Sinai Cancer Center ( Site 0009), Miami Beach, Florida +1 locations
Conditions: Malignant Neoplasm
Register for Updates
The Effect of Multimodal Pain Regimen on Use of Narcotics After Rotator Cuff Tear Repair
NCT07076069
Recruiting
The goal of this clinical trial is to understand which group of pain control medications work best in adults after rotator cuff surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Montefiore Hutchinson Campus, Bronx, New York
Conditions: Rotator Cuff Repairs, Pain Management
Register for Updates
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
NCT06991257
Recruiting
The purpose of this study is to learn about the safety and effects of the study medicine (PF-07328948) for the possible treatment of heart failure (HF).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: National Heart Institute, Beverly Hills, California +23 locations
Conditions: Heart Failure
Register for Updates
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
NCT07002216
Recruiting
The purpose of this study is to further assess the efficacy and tolerability of a regimen of Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone (BrECADD) in patients with Stage 2 B-IV Hodgkin Lymphoma (HL) with an exploratory objective to assess the clinical utility of Circulating tumor DNA (ctDNA) as a biomarker for minimal residual disease (MRD) and depth of treatment response.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
08/12/2025
Locations: University of Miami, Miami, Florida
Conditions: Hodgkin Lymphoma, Advanced Hodgkin Lymphoma
Register for Updates
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
NCT07104383
Recruiting
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Viking Clinical Site #2037, Birmingham, Alabama +111 locations
Conditions: Weight Loss
Register for Updates
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT06991556
Recruiting
This Phase II study aims to evaluate efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg once a day (QD) doses + abiraterone compared with an androgen receptor pathway inhibitor (ARPI, abiraterone or enzalutamide) in participants with metastatic Hormone Sensitive Prostate Cancer (mHSPC) and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and PK data from partici... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Urology Cancer Center PC, Omaha, Nebraska +3 locations
Conditions: Metastatic Hormone-sensitive Prostate Cancer
Register for Updates
The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls
NCT07051668
Recruiting
Sepsis is a leading cause of death in children, and an early diagnosis that improves outcomes is less likely in children who are treated in general Emergency Departments (EDs), that treat adults and children, compared to pediatric Emergency Departments. The study team, in collaboration with invested clinicians and expert partners, has developed a pediatric sepsis diagnostic safety toolkit that we will implement in a pediatric health system's transfer call center. Preparation for launch of the to... Read More
Gender:
ALL
Ages:
1 month and above
Trial Updated:
08/12/2025
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Sepsis, Diagnosis, Emergencies
Register for Updates
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
NCT07003425
Recruiting
This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will coincide with the last visit of the Maintenance Period in the Parent Study 2) Extended Treatment Period 3) Post-treatment Follow-up Period. This study will be conducted in participants with atopic de... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Investigational Site, Fountain Valley, California +31 locations
Conditions: Atopic Dermatitis
Register for Updates